adamis Pharmaceutical is up 1.3% to $9.29.
The company has been one of the most active players in the drug industry and has been investing heavily in its product development.
The stock has climbed about 2% this year.
Eisai Pharmaceuticals, which has been developing a new drug to treat an aggressive form of liver cancer called Langerhans Disease, was also up.
Eisai was acquired by the Eli Lilly company earlier this year and is the largest publicly traded pharma company in China.
The deal was expected to close in the second quarter.
Eisenkotz Pharmaceuticals rose 2.6% to a record high of $1.85.
The drug maker has been aggressively pursuing new and improved therapies to treat the aggressive form, known as cystic fibrosis.
The new drug is being developed by its Chinese partner, Jingbao Pharmaceuticals.
Eizenberg Pharmaceuticals was up 0.5% to 2.1 times earnings.
The pharma giant, which was acquired earlier this month by Roche Holding AG, was already the largest pharmaceutical company in the world and was considered one of its largest stockholders.
It’s also one of Alibaba Group Holding Ltd’s largest shareholders.
Einstein Pharmaceuticals climbed 1.6%.
The company is developing a novel cancer drug to fight metastatic melanoma and is also expanding its business globally.
Einstein’s business is in the early stages of expansion, but its stock has jumped about 4% this past year.
The stock rose in early April when the company announced it would open a clinical trial of its drug in patients with advanced breast cancer.
In August, Einstein announced that it would launch a phase 3 clinical trial in breast cancer patients.
The test will test its drug’s ability to treat patients with lung cancer.
Eli Lilly & Co said it had no comment.